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INTRODUCTION
This review will discuss the effects on vision and 
the eye of medications commonly prescribed for 
women diagnosed with early-stage breast cancer 
(BC). After this introduction, the text will be divided 
into three main sections, each corresponding to a 
 different  treatment phase: (1) adjuvant chemotherapy 
administered for months shortly after a BC diagnosis 
and surgery, (2) adjuvant endocrine therapy used 
thereafter for years in order to reduce the risk of BC 
recurrence, and (3) supplemental medication used as 
needed to alleviate or counteract the side effects of the 
BC medications. A final concluding section suggests 
directions for future research. This review will focus 
on medications that appear to affect the visual system 
in more than rare and isolated cases and are part of 
the standard-of-care armamentarium for early-stage 
BC. The term “adjuvant” denotes treatments used for 
reducing the risk of disease recurrence.
Because cancer medications interfere with cell 
growth or proliferation, they tend to be especially toxic 
to normal tissues: (a) that have a high rate of  cellular 
turnover, (b) that have a high biochemical and/or 
anatomical vulnerability to a given  medication, and 
(c) that are sufficiently exposed to the medication. 
This combination of factors probably helps explain 
why excessive tearing (i.e., epiphora, which involves 
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Alvin Eisner1 and Shiuh-Wen Luoh2,3
1Women’s Health Research Unit, Department of Obstetrics & Gynecology, Oregon Health & Science University, 
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ABSTRACT
This review concerns the effects on vision and the eye of medications prescribed at three phases of treatment 
for women with early-stage breast cancer (BC): (1) adjuvant cytotoxic chemotherapy, (2) adjuvant endocrine 
therapy, and (3) symptomatic relief. The most common side effects of cytotoxic chemotherapy are epiphora and 
ocular surface irritation, which can be caused by any of several different regimens. Most notably, the taxane 
docetaxel can lead to epiphora by inducing canalicular stenosis. The selective-estrogen-receptor-modulator 
(SERM) tamoxifen, long the gold-standard adjuvant-endocrine-therapy for women with hormone-receptor-
positive BC, increases the risk of posterior subcapsular cataract. Tamoxifen also affects the optic nerve head 
more often than previously thought, apparently by causing subclinical swelling within the first 2 years of use 
for women older than ~50 years. Tamoxifen retinopathy is rare, but it can cause foveal cystoid spaces that are 
revealed with spectral-domain optical coherence tomography (OCT) and that may increase the risk for  macular 
holes. Tamoxifen often alters the perceived color of flashed lights detected via short-wavelength-sensitive (SWS) 
cone response isolated psychophysically; these altered perceptions may reflect a neural-response  sluggishness 
that becomes evident at ~2 years of use. The aromatase inhibitor (AI) anastrozole affects perception similarly, 
but in an age-dependent manner suggesting that the change of estrogen activity towards lower levels is more 
important than the low estrogen activity itself. Based on analysis of OCT retinal thickness data, it is likely 
that anastrozole increases the tractional force between the vitreous and retina. Consequently, AI users, myopic 
AI users particularly, might be at increased risk for traction-related vision loss. Because bisphosphonates are 
sometimes prescribed to redress AI-induced bone loss, clinicians should be aware of their potential to cause 
scleritis and uveitis occasionally. We conclude by suggesting some avenues for future research into the visual 
and ocular effects of AIs, particularly as relates to assessment of cognitive function.
Keywords: Aromatase inhibitor,  Dry eye,  Estrogen, Retina, Short-wavelength-sensitive cones, Tamoxifen
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the interplay between tear production, the ocular 
surface, and tear drainage)1–3 occurs as a side effect of 
several BC chemotherapeutic medications.4 Although 
all side effects are manifestations of  chemical toxicities, 
some side effects − most notably those  resulting from 
the  virtual abolition of estrogen synthesis caused by 
inhibition of the enzyme aromatase5,6− might be viewed 
also as consequences of accelerated aging.7 This view is 
important because patients’ symptoms or complaints 
(e.g., increased floaters) might too often be  misattributed 
to natural aging rather than to treatment effects.
As detailed later, two distinct classes of adjuvant 
endocrine medications are now widely prescribed 
expressly for women whose BC was identified as 
hormone-receptor-positive.8 Selective estrogen  receptor 
modulators (SERMs) act against BC by occupying 
 estrogen receptors (ERs), while aromatase  inhibitors 
(AIs) act against BC by interfering with  estrogen 
 synthesis.9 We will feature the endocrine-therapy 
 portion of this review for a variety of reasons, the most 
central being that millions of healthy BC survivors in 
the foreseeable future are projected to use such medica-
tions on an adjuvant basis for years at a time.8,10–13 Four 
additional sets of reasons are listed next; each reflects 
the rapid evolution of basic science and clinical care.
First, overwhelming evidence is accumulating to 
show that estrogenic activity directly impacts a vast 
array of physiologic functions beyond those involving 
reproductive and sexual function.6,14 Estrogen receptors 
(ERs) are present throughout the body, including the 
anterior15–18 and posterior19,20 portions of the human eye 
and also in the lacrimal18,21 and meibomian glands18,22,23 
responsible for protecting the surface of the eye. In 
fact, ERs are present throughout the central nervous 
system (CNS),24–27 so changes in estrogenic activity 
have the potential to affect central visual processing, in 
 addition to ocular visual processing. Moreover, because 
 estrogens are synthesized locally throughout the body, 
much estrogenic activity is autocrine or paracrine, 
rather than endocrine.28 These autocrine and paracrine 
estrogenic actions take on increased importance for 
post-menopausal women, whose estrogen supplies 
have decreased markedly.29
Second, the longstanding standard-of-care for 
 hormone-receptor-positive early-stage BC is  changing. 
That is, use of the SERM tamoxifen (Nolvadex®) as 
adjuvant endocrine therapy is being supplanted by the 
use of AIs such as anastrozole (Arimidex®) or letrozole 
(Femara®) for women who are post-menopausal.30 
Because the traditional 5-year period of adjuvant 
endocrine therapy was based on studies involving 
only tamoxifen,31 this period may be lengthened in the 
future, depending on the outcomes of ongoing clinical 
trials with AIs.31,32 These changes in adjuvant endocrine 
therapy raise  concerns for long-term eye health, since 
a prolonged period of sustained estrogen deprivation 
has the  potential to increase the risk or severity of 
 several age-related eye diseases or conditions, including 
glaucoma33–37 and macular degeneration.38–41 Moreover, 
because AIs are notorious for reducing bone density,42,43 
any visual dysfunction− no matter how subtle− that 
raises the risk of falling will consequently raise the risk 
of fracture, even in the short-term.44 This cascade of 
events may lead to potentially devastating outcomes 
among at-risk BC survivors.
Third, because adjuvant endocrine medications are 
self-administered orally on a daily basis, they often 
are considered by patients to be more elective than 
the  preceding chemotherapy45 which is administered 
intravenously in a clinical setting. Thus, adherence to 
adjuvant endocrine therapy often ends prematurely or 
becomes sub-optimal for any of a variety of reasons,46,47 
including the patient’s perceived quality-of-life/side-
effect tradeoffs.48,49 The net consequence is that real-
world BC recurrence rates exceed those reported in 
clinical trials.50 This set of events is especially unfortu-
nate since greater side-effect severity signifies a better 
chance of BC non-recurrence,5,51 probably because the 
severity of AI-induced side effects corresponds to the 
degree of biologically relevant estrogen suppression.51 
Thus, the more reliably side effects can be recognized 
by clinicians and hence addressed, the better patients’ 
cancer outcomes are likely to be.
And fourth, the recent wide use of AIs provides 
a novel means for evaluating the ways by which 
 estrogen may support healthy eyes and normal vision. 
Many women diagnosed with early-stage BC or with 
 precancerous conditions such as ductal carcinoma in situ 
(DCIS) or lobular carcinoma in situ (LCIS) will use AIs 
but never receive cytotoxic chemotherapy,52,53 so these 
women comprise a minimally confounded cohort for 
short- and long-term studies of estrogen  deprivation in 
adults. Parallel studies can be conducted using  animal 
models.
CHEMOTHERAPEUTIC AGENTS USED 
SHORTLY AFTER BC DIAGNOSIS
Although it would be desirable to specify the frequen-
cies with which ocular side effects such as “dry eye” 
(also called keratoconjunctivitis sicca) result from any 
individual medication, several factors combine to make 
such estimates uncertain. First, cytotoxic chemothera-
peutic agents rarely are administered entirely indepen-
dently of one another. Second, toxicities typically are 
cumulative-dose-dependent, and side effects need 
not manifest immediately following the most recent 
 treatment. Third, the physiologic responses to treatment 
can differ for individual patients. In fact, the  recognition 
and prospective identification of salient  individual 
differences provides the basis for “personalized 
 medicine”, which is being implemented in the clinic at 
an accelerated pace owing for a variety of scientific and 
 technological advances.54,55 And fourth, the frequency 
with which symptoms are reported depends greatly on 
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the expectations and communications among  providers, 
investigators, and patients.56,57 No studies appear to 
have been conducted wherein validated survey tools 
(e.g., the Ocular Surface Disease Index (OSDI)58) have 
been used for assessing ocular-surface discomfort stem-
ming from chemotherapy, for example. Neither do there 
appear to be any epidemiologic studies addressing the 
relation of chemotherapy to dry eye.
Bear in mind that the term dry eye is somewhat of 
a misnomer in the sense that the eyes of people with 
dry eye can be quite watery, typically because tears 
are produced reflexively to counteract the ocular 
surface discomfort.59 However, occlusion of the tear 
drainage apparatus may contribute occasionally to 
ocular irritation,1,60 and it can allow toxic agents to 
remain in contact longer with the ocular surface. Dry 
eye  syndrome is diagnosed largely according to the 
 presence of subjective symptoms of discomfort, such 
as a “gritty” sensation,61 and it occurs most often among 
post-menopausal women,3,62 who coincidently are the 
people most likely to develop BC.63
As discussed next, epiphora and ocular surface 
discomfort may result from several different cytotoxic 
chemotherapy regimens, and as discussed later, there 
is reason to hypothesize that AI usage may contribute 
to dry eye. In addition to being locally irritating or 
otherwise bothersome,64 epiphora may cause the tear 
film layer to become asymmetric (thickest at the inferior 
margin of the pupil), leading to coma-like aberrations 
and decreased optical quality (vertical “comet tails”) 
after blinking.65
From about 1990 until quite recently, the most  common 
chemotherapeutic regimen for early-stage BC consisted 
of a 2-drug combination (an anthracycline plus cyclo-
phosphamide) administered intravenously four times 
over a period of ~2 months.66 Because the  anthracycline 
used most often is doxorubicin (Adriamycin®), this 
treatment usually is referred to as”AC” chemotherapy. 
Anthracyclines (also including epirubicin) and cyclo-
phosphamide (Cytoxan®) each interfere with DNA 
 replication via multiple mechanisms. A prominent effect 
of the topoisomerase-poison doxorubicin is to intercalate 
DNA,67 while the alkylating-agent cyclophosphamide is 
a prodrug that after hepatic conversion leads to cross-
linkages between DNA strands.68,69 The package insert 
for doxorubicin states that “conjunctivitis, keratitis, and 
lacrimation occur rarely”, and while dry eye apparently 
due to treatment with cyclophosphamide has been 
reported for some non-BC patients,70 the package insert 
makes no mention of ocular or visual effects. Although 
at least several secondary sources cite articles reporting 
doxorubicin to cause watery eyes or conjunctivitis in 
25% of users, the strongest statement we could locate 
in these earlier articles was by Blum,71 who commented 
“… some patients report increased lacrimation…”
The standard of care for early-stage BC is changing, 
in that taxanes now often are included in the chemo-
therapy regimen.72 Taxanes act against BC by stabilizing 
microtubules, thereby inhibiting mitosis.73,74 Two 
 different taxanes− docetaxel (Taxotere®) and paclitaxel 
(Taxol®)− have been FDA-approved as treatments for 
early-stage BC, and a 4-cycle Taxotere/Cytoxan [“TC”] 
regimen with docetaxel has begun to replace the 4-cycle 
AC regimen. This change follows the 2009 publication 
of results from a clinical trial directly comparing the two 
regimens.75 In practice, paciltaxel tends to be used in 
sequential regimens, e.g., with AC administered first.76,77 
Docetaxel may be administered on either a weekly 
or, more commonly, a tri-weekly (i.e., once per three 
weeks) schedule,78 but the tri-weekly schedule with 
co- administration of cyclophosphamide is the most 
 common  regimen for early-stage BC. Docetaxel may 
also be given in various other regimens.79–81
 There is abundant evidence showing that  docetaxel 
often leads to epiphora.64,82 In contrast, there is limited 
evidence showing that paclitaxel leads to epiphora,83 
and this limited evidence is disputed as being 
 artifactual.84 Docetaxel can be present in tears,85 and it 
leads to  epiphora mainly by causing canalicular steno-
sis in the lacrimal drainage apparatus.86 The severity 
and frequency of epiphora is less with the tri-weekly 
dosing schedule,87 but since published  studies used 
the longer treatment regimens for metastatic BC,87–89 
reported frequencies of epiphora (as high as ~40% for 
tri-weekly treatments vs. ~65% for weekly treatments)87 
would overestimate the corresponding frequencies 
for early-stage (or shorter)89 treatment  regimens. 
Based on our clinical experience (author SWL), about 
1–2% of  early-stage BC patients spontaneously report 
 experiencing epiphora by the end of a 4-cycle TC 
regimen. We expect the percentage would be higher if 
patients were queried.
The taxanes, perhaps more so paclitaxel,90,91 are notori-
ous for causing peripheral sensory neuropathies,92 which 
arise at least partly from the ability of taxanes to stabilize 
microtubules in neurons93 not sufficiently  protected by 
the blood/brain barrier.94 If this barrier is compromised, 
taxanes might affect visual function directly. Paclitaxel 
has been reported to alter  electroretinographic and 
pattern-visual-evoked potentials,95 and possibly optic 
nerve response.96 There are several case reports of 
taxane-associated cystoid macular edema occurring in 
the absence of visible angiographic leakage.97–102
The first standard chemotherapeutic regimen for 
early-stage BC, still in use today, consists of a “CMF” 
drug triad of cyclophosphamide, methotrexate, and 
5-fluorouracil [5-FU].103 The anti-metabolites metho-
trexate (an anti-folate)104 and 5-FU105 each interfere 
with DNA replication and RNA synthesis via multiple 
 mechanisms, with each drug acting independently to 
inhibit thymidine synthesis. Although the anti-cancer 
actions of docetaxel and 5-FU are distinct, 5-FU can 
cause canalicular stenosis at least occasionally,106–110 
 suggesting an inherent vulnerability of the ocular 
drainage apparatus. Epiphora occurs in ~25% or more 
of patients administered 5-FU,110–112 and several  studies 
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have reported systemically administered 5-FU to be 
present in tears.111,113 There are anecdotal reports of 
low doses of  methotrexate leading to ocular surface 
inflammation,114 and based on clinical trial results, 
 conjunctivitis occurs for a higher percentage of BC 
 survivors on a CMF regimen than on an FAC regimen115 
(i.e., conjunctivitis occurs more often when methotrex-
ate is used in place of doxorubicin).
About 15–25% of early-stage BC patients have tumor 
cells that test positive for the overexpression of Human 
Epidermal growth factor Receptor 2 (HER2),116–118 a cell 
membrane protein that modulates many signaling path-
ways important for cell growth and proliferation.119,120 
Trastuzamab (Herceptin®), a HER2-binding monoclo-
nal antibody with multiple mechanisms of anti-cancer 
action,121 was FDA-approved in 2006 for early-stage BC, 
and it is now a mainstay of treatment for early-stage 
BC patients whose tumors test positive for HER2.122 
Trastuzamab may be prescribed for early-stage BC in 
any of several chemotherapeutic combinations, which 
may involve periodic administration of trastuzamab for 
up to a year.123 In addition to the drugs mentioned in the 
preceding paragraphs, trastuzamab-containing chemo-
therapeutic regimens may include the platinum-based 
DNA adduct carboplatin.124 Trastuzamab apparently can 
cause conjunctivitis in a small percentage of patients.125 
We can find no evidence for carboplatin affecting the 
eye or vision at the doses used for early-stage BC.
We conclude this section by noting: (1) that a large but 
somewhat controversial literature is emerging regarding 
the ability of cytotoxic (and endocrine)  chemotherapies 
to induce cognitive changes  collectively termed 
 chemobrain (or chemofog),126–130 (2) that all  cognitive test-
ing batteries rely on sensory (visual and/or  auditory) 
input to subjects or patients, and (3) that testing  batteries 
typically include tests involving higher-order visual 
information processing or retrieval capabilities.131, 132 
Details are outside the scope of this review.
ADJUVANT ENDOCRINE THERAPY
As mentioned earlier, two classes of drugs− SERMs and 
AIs− are widely used as adjuvant endocrine therapy for 
women with hormone-receptor-positive early-stage BC.8,9 
The classical view is that by competitively occupying 
ERs, SERMs act as (a) ER-agonists or (b) ER-antagonists 
according to whether the SERM stimulates the ER or 
instead does not stimulate the ER; in the latter case the 
ER is prevented from functioning appropriately as it 
would if stimulated by an estrogen.133 The SERMs used 
against BC act as ER-antagonists in breast tissue,134,135 
at least for the first several years of treatment,136,137 and 
the mainstay SERM tamoxifen reduces the risk of BC 
recurrence for women of all ages,138 and also for men.139 
The ability of SERMs to function as ER-antagonists in 
some tissues but as ER-agonists in other tissues depends 
upon many factors, including the tissue-dependent 
distribution of the ERα and ERβ subtypes,137,140 and 
even on the activity of HER2.141 ERα and ERβ each are 
present within the neural retina of men and women, 
with ERα apparently distributed more uniformly but 
exhibiting greater interpersonal variation.20 ERα and 
ERβ are present also within the pigment epithelium of 
men and women,19 where tamoxifen has been reported 
to decrease glutamate uptake, for example.142 Less is 
known about the presence of ERs within portions of the 
visual system beyond the eye, and effects of SERMs on 
ERα vs. ERβ activity are yet to be adequately delineated 
for any level of the visual system.
AIs act entirely differently. By interfering with the 
actions of the enzyme aromatase, which catalyzes the 
conversions of androgens to estrogens,6,28 AIs almost 
completely abolish estrogen synthesis at its sources for 
women who are post-menopausal, whether naturally or 
surgically.143 By themselves, AIs are not effective for use 
in pre-menopausal women because the initial reduction 
in ovarian estrogen synthesis triggers feedback loops 
in the hypothalamic-pituitary-gonadal axis that serve 
to relieve this reduction.144 However, several clinical 
trials are underway to determine whether using an AI 
concomitantly with a gonadotrophin-releasing hormone 
(GnRH) agonist to disrupt this feedback system might 
reduce the risk of recurrence for pre-menopausal women 
with early-stage BC.145 Although male BC patients some-
times are prescribed AIs off-label, circulating estrogen 
levels may be reduced only incompletely for men with 
 testicular function.146 Overall, the information regarding 
the use of AIs for male BC is quite limited.147–149
ERs may function genomically or non-genomically 
according to whether the ERs are present within a cell 
or on the cell membrane, and they may act over long 
(e.g., hours to days) or short (e.g., msec to sec) times-
cales, respectively.27,150–152 Thus, ER-dependent effects of 
SERMS and of AIs on vision may be mediated by either 
genomic or non-genomic means. However, none of the 
effects described in the subsequent text can be assigned 
confidently to one means or the other, and of course, 
some effects may occur indirectly, e.g. via alterations in 
blood flow.153 Moreover, several of the ocular effects in 
particular probably involve collateral or separate drug 
actions; these are identified in the text.
Before proceeding, we note that the next two sections 
(on the SERM tamoxifen, and on AIs) each contain some 
previously unpublished data from human subjects. All 
these data were obtained using protocols approved by 
the OHSU Institutional Review Board and the OHSU 
Cancer Institute, and all protocols were conducted in accor-
dance with the tenets of the Declaration of Helsinki.
The SERM tamoxifen
Three different SERMs− tamoxifen, raloxifene (Evista®), 
and toremifene (Fareston®)− are used to help prevent 
or treat BC.135 However, tamoxifen is the only SERM 
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FDA-approved as adjuvant therapy for early-stage 
BC, and it is the only SERM approved for every BC 
stage, from the prophylactic through the metastatic 
settings. A fourth SERM, clomiphene (Clomid®) has 
long served as the standard-of-care fertility drug for 
inducing ovulation,154 and tamoxifen was used for this 
purpose before  receiving approval as a BC treatment.155 
Clomiphene sometimes leads to perceptible vision 
changes,156,157 especially when the dose is increased by 
a factor of up to four from the customary 50 mg/day 
starting dose, to achieve  pregnancy.158 Known visual 
disturbances with clomiphene can include palinopsia 
(a prolonged afterimage, often with a trailer),156,157 pho-
topsia (entoptic flashing lights),158 and scotomas.159 In 
addition, temporal resolution may be reduced slight-
ly.156 Tamoxifen, clomiphene, and toremifene each have 
triphenylethylene structures, while raloxifene has a 
benzothiophene structure.135 The biochemical similar-
ity of tamoxifen with clomiphene coupled with the 
exceedingly long ER-binding times for clomiphene160 
raise the possibility that some of the striking effects of 
clomiphene may be related to visual or ocular effects of 
tamoxifen that are more subtle or infrequent.
Tamoxifen is mainly a prodrug in the sense that two of 
its many metabolites, notably 4-hydroxy-N- desmethyl-
tamoxifen (endoxifen) and also 4-hydroxytamoxifen 
(4-OHT), now are known to have much greater  affinity 
for ERs than does tamoxifen itself.161,162 The serum 
concentration of 4-OHT normally is even lower than 
that of endoxifen, so endoxifen is considered the most 
important metabolite.161 To the best of our knowledge, 
only one study has related visual-system side effects 
to assessment of any tamoxfien metabolites. Gallicchio 
et al.163 found that 13 of 97 tamoxifen users self-reported 
unspecified vision problems and that these 13 women 
had significantly higher serum concentrations of tamox-
ifen and N-desmethyl-tamoxifen (N-DMT) than did the 
84 women not reporting vision problems. N-DMT is a 
precursor metabolite that is hydroxylated to endox-
ifen via action of the enzyme CYP2D6.161 Gallicchio 
et al.163 did not measure endoxifen levels. CYP2D6 
activity  varies greatly among individuals depending 
upon which CYP2D6 alleles a person has,164 and this 
factor with other genetic information are now consid-
ered in the development of “personalized” treatment 
regimens.54,55,164 HER2 status and hormone-receptor 
status also are factors.
(CYP2D6 is a member of the cytochrome P450 
 super family of heme-containing membrane proteins 
responsible for the hepatic metabolism of the large major-
ity of clinically active drugs.165 See also the Redressing Side 
Effects section for information on CYP2D6 specifically.)
When tamoxifen was first prescribed in the late 1970s 
as a treatment for advanced BC, the doses were many 
times higher than they are now, and several case studies 
were published in the early 1980s concerning tamox-
ifen retinopathy.166,167 Tamoxifen retinopathy classically 
is characterized by the presence of small crystalline 
 deposits that may occur in the nerve fiber and inner 
plexiform layers near the fovea, sometimes accompa-
nied by edema.168,169 Although tamoxifen retinopathy 
typically is considered to depend on total cumulative 
dose,168 spectral-domain optical coherence tomogra-
phy (OCT) can reveal foveal cystoid spaces within only 
a year or two of the start of tamoxifen use for some 
patients on contemporary dosing levels,170 which are 
20 mg/day.
The reported prevalence rates of tamoxifen retin-
opathy for BC survivors using standard doses vary 
 substantially between studies, from less than 1%171,172 
to about 6%,173 with estimates from additional studies 
 falling within this range.174–176 This variation may be 
in part due to the uncertainty and/or subjectivity in 
detecting tamoxifen retinopathy photographically,169 
particularly since only a few isolated crystals typically 
are found, and the presence of age-related changes at 
the fundus can make interpretation difficult.168,175,176 It is 
also possible that some yet undetermined factors cause 
incidence rates to vary across diverse populations. No 
subjects with tamoxifen retinopathy were identified in 
the 98 sets of fundus photographs evaluated for author 
AE’s studies (2 eyes per subject, 74 of the subjects 
were at least 6 months amenorrheic).177 The subjects in 
Eisner’s studies178–184 were selected for excellent visual 
acuity and normal reading vision, however, which could 
have contributed to the observed zero prevalence rate.
In our view, the initial findings of tamoxifen 
 retinopathy at an auspicious time in the evolution 
of BC treatment have led to an overemphasis on this 
 condition in the sense that vision symptoms (e.g., 
 photopsia) due to other intraocular conditions may 
be too readily  misattributed to tamoxifen retinopa-
thy and/or  downplayed. Small numbers of crystals 
seem not to cause acuity loss, while mild acuity loss 
accompanying edema can be reversed by withdrawing 
the tamoxifen.168,173 The development of foveal cystoid 
spaces might be more serious since it may contribute to 
the subsequent development of macular holes,185 which 
are reported to occur in tamoxifen users at a rate about 5 
times that of women not using tamoxifen.186 (Most of the 
tamoxifen users in this study186 were on 20 mg/day but 
a few were on 40 mg/day; Robert Bourke, MD, personal 
communication). Other possible causes of this elevated 
prevalence rate are discussed in the portion of the next 
section regarding vitreo-retinal traction.181
Numerous researchers have suggested that tamoxifen 
retinopathy is not caused by the actions of tamoxifen 
on ERs, but stems instead from tamoxifen’s cationic 
amphiphilic properties, which resemble those of 
 chloroquine.187 If this suggestion is correct, then post-
menopausal women who develop tamoxifen retinopa-
thy may simply be switched to an AI for relief. Similarly, 
because tamoxifen, chloroquine, and other related drugs 
all can lead to vortex keratopathies,188 post-menopausal 
tamoxifen users who develop  corneal epithelial deposits 
may likewise be switched to an AI. Corneal deposits 
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have been reported in as few as 0%169,175,189 to as high 
as 72% of women using a standard dose of tamoxifen, 
with the presence of these deposits depending on the 
 duration of use.174,190 The wide discrepancy arguably 
results from a combination of two factors: (1)  differences 
in the sensitivity of the means by which the cornea is 
assessed, and (2) the subtlety of the deposits.190 However, 
other hypothetically pertinent factors (e.g., amount of 
sunlight exposure)191 might also affect the observed 
 frequencies. Regardless, even  readily observable corneal 
deposits are reversible174 and not sight-threatening.168
Tamoxifen can induce cataracts, particularly poste-
rior subcapsular cataracts, in many users.169 In separate 
clinical trials regarding BC prophylaxis, tamoxifen users 
were found to have a significantly higher incidence of 
cataracts and cataract surgeries compared to a placebo 
group192 and to raloxifene users,193 and an independent 
survey of BC survivors found that women who used 
tamoxifen for the standard 5-year term were more 
likely than non-users to have seen a physician about 
cataracts.194 With one exception,195 studies not finding 
statistical significance display corresponding trends in 
the data nevertheless.196,197 Moreover, several animal 
model studies have reported that tamoxifen induces 
cataracts.198–200 The mechanism of cataract induction 
involves the blockage of swelling-activated  chloride 
channels in the lens,201,202 and it is at least partly 
 independent of the actions of tamoxifen on ERs.203,204 The 
increased risk of posterior subcapsular cataracts may be 
as high a factor of 4,169 which is important because poste-
rior subcapsular cataracts tend to impair function more 
than other types of cataracts.205 This visual impairment 
may adversely affect cognitive test performance, even at 
a time when visual acuity is affected minimally.206
 Clinically evident optic neuritis resulting from 
tamoxifen use has been reported in only isolated 
cases,174,207–210 but the optic nerve may be affected often 
at a subclinical level. Eisner et al.,178 using scanning laser 
 ophthalmoscopy, found that the optic cup dimensions 
of short-term (≤ 2 years) middle-aged (51–69 years) 
 early-stage BC tamoxifen users were appreciably smaller 
than those of (a) female control subjects  without BC 
 histories and not using hormonal medications, and also 
(b) a corresponding group of early-stage BC  anastrozole 
users. The cup dimensions of longer-term  tamoxifen 
users211 and of younger tamoxifen users178 were 
 indistinguishable from those of control subjects. (One 
may  speculate that this latter result occurred because 
the younger tamoxifen users were not yet menopausal 
despite being amenorrheic.212, 213) The dependence of 
cup size on the duration of tamoxifen use is  noteworthy 
since it is the opposite of what would occur if the effect 
of tamoxifen on the optic nerve head (ONH) were due 
to a cumulative dose toxicity. The smaller cup sizes− 
which were within the range of normal and thus would 
be regarded as unremarkable if observed on an individ-
ual basis without baseline data for comparison− were 
consistent with astrocytic swelling.178
The first study to assess the visual function of a 
population of tamoxifen users using measures other 
than visual acuity was that of Gorin et al. in 1998.169 
They found that tamoxifen users’ color discrimination 
tended to be slightly compromised as assessed with 
the Farnsworth Desaturated Panel D-15 test. No axis of 
loss (e.g., tritanopic) was specified. Ritter et al.214 used 
this same test to reveal color discrimination deficits 
in five of six visually symptomatic tamoxifen users, 
and Salomao et al.215 reported that two of 19 visually 
asymptomatic tamoxifen users had diffuse color vision 
defects as assessed with the FM-100 hue test. Gorin 
et al.169 also reported that neither visual-field macular 
sensitivities (pattern 10-2) nor high- nor low-contrast 
visual  acuities appeared to be altered. In unpublished 
results, we (author AE) found the contrast sensitivities of 
 tamoxifen users (assessed with the Pelli-Robson chart) 
to be indistinguishable from those of female control 
subjects. All the tamoxifen users whom we tested met 
a set of strict eligibility criteria that included excellent 
acuity and passing a conventional color vision screening 
(a standard D-15 test), and no subjects showed signs of 
tamoxifen retinopathy.
Even with our strict eye-health eligibility criteria in 
place, however, visual responses mediated via short-
wavelength-sensitive (SWS) cones were found to be 
affected often, both in the visual-field periphery180 and 
at the fovea.184 In particular, visual thresholds assessed 
with Short Wavelength Automated Perimetry (SWAP) 
were related systematically to the duration of tamoxifen 
use, with the peripheral SWAP sensitivities of long-term 
users (> 2 years) lower than those of short-term users 
(≥ 4 months, ≤ 2 years).180 There was no suggestion of any 
corresponding effect for Frequency Doubling Perimetry 
(FDP),180 implying that a duration-of-use effect does not 
occur for all types of visual-field tests and suggesting 
that it may occur preferentially or selectively for vision 
mediated via SWS cones. The strong dependence of 
SWAP sensitivities on retinal eccentricity coupled with 
the strict eye-health eligibility criteria and normal 
 contrast sensitivities make it unlikely that the observed 
effects on SWAP resulted from lenticular change.
Although the magnitude of the SWAP visual-field 
effect decreased towards the center of the visual 
field,180 SWS-cone-mediated response evidently was 
affected at the fovea also.184 That is, tamoxifen users 
as a group were more likely than non-BC control 
 subjects to  perceive a short-wavelength incremental 
test stimulus on a yellow adapting background as 
“white” rather than as colored. Moreover, long-term 
users were  significantly more likely than short-term 
users to  perceive this stimulus as “white” despite not 
having a selective reduction of SWS-cone-mediated 
sensitivity at the fovea,184 The absence of a foveal sen-
sitivity loss implied that the perception of white did 
not result from an acquired tritanopic defect, as might 
otherwise have been assumed, and estimates of lens 
density obtained psychophysically183 were  unrelated to 
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the choice of color name ( unpublished results). Instead, 
the perception of white more likely resulted from an 
acquired  temporal-response sluggishness that caused 
the color from the short-wavelength test stimulus to 
combine, rather than to contrast, with the color from 
the yellow background stimulus.182 Given the  stimulus 
parameters used for SWAP, a prolongation of the tem-
poral integration (i.e., neural summation) periods for 
SWS-cone-mediated response would be expected to 
account for at least part of the long- vs. short-term dif-
ferences observed in the periphery of the SWAP visual 
field.179 Related results from various human subject 
studies involving gender216, 217 or hormonal change218–222 
collectively suggest that the ability of tamoxifen to alter 
SWS-cone-mediated responses involves the actions of 
tamoxifen on ERs.
The striking change in color perception at about 
2 years duration-of-use (see Figure 1) in this cross-
sectional study184 presumably resulted from changes in 
the body’s response to sustained tamoxifen exposure, 
perhaps as an acquired resistance began to develop.223 
In any event, the data provided evidence for the abil-
ity of tamoxifen to materially affect at least one CNS 
 neural substrate, possibly by altering its timing in 
response to lights flashed for several hundred msec. 
This may have pertinence for studies of cognitive 
 function in BC survivors using tamoxifen or other 
adjuvant endocrine therapies,224 especially if the color 
perception change is proven to be a consequence of 
reduced neural  processing speed. While there appear 
to be no studies of clomiphene and SWS-cone-mediated 
response  corresponding to those described in the preced-
ing two paragraphs, the ability of clomiphene to cause 
 palinopsia may be regarded as an extreme example of 
a prolonged visual response.
Little is known regarding the specific physiologic 
means by which tamoxifen affects SWS-cone-mediated 
vision or any other visual response. ERs are present 
in all layers of the neural retina,20 but how these ERs 
are affected individually or concertedly by tamoxifen 
remains undetermined. Nor is it known what roles ERs 
may have for supporting vision other than to contrib-
ute to neuroprotection.225–227 Interpreting the effects of 
tamoxifen on SWS-cone-mediated response is further 
complicated by the potential for cortical effects and 
also by the possible salience of effects not depending 
exclusively on the actions of ERs. The electroretino-
grams (ERGs) of clinically asymptomatic tamoxifen 
users are affected little or not at all,215,228 but because 
conventional full-field and multifocal white-light 
ERGs each are insensitive to alterations of SWS-cone 
 mediated response, functional alterations to retinal SWS 
cone pathways would not be evident if they existed. To 
understand how ER activity affects vision, it probably 
is more straightforward to investigate the effects of AIs 
rather than SERMs.
Aromatase Inhibitors: Anastrozole 
(Arimidex®), Letrozole (Femara®), and 
Exemestane (Aromasin®)
Three third-generation AIs have received FDA-approval 
for use as adjuvant endocrine therapy in early-stage BC. 
Anastrozole (1 mg/day) and letrozole (2.5 mg/day) 
were approved in 2002 and 2005, respectively, as first-
line monotherapy, while  exemestane (25 mg/day) cur-
rently is approved for use after 2–3 years of tamoxifen 
use, for a total of 5  continuous years of adjuvant endo-
crine therapy. In practice,  however, oncologists exercise 
substantial discretion in deciding which adjuvant endo-
crine medications to prescribe to individual patients. 
Clinical trials are well underway to determine whether 
switching regimens, with tamoxifen used for the first 
2–3 years and then an AI for the balance of the conven-
tional 5-year adjuvant endocrine period, are more effec-
tive than a comparable period of monotherapy.229 Trials 
also are well on their way regarding the efficacy and 
safety of extending the duration of adjuvant endocrine 
therapy beyond 5 years.31,230,231
There are two broad classes of AIs: non-steroidal 
and steroidal. Anastrozole and letrozole each are non-
 steroidal AIs that by reversibly binding to the  aromatase 
enzyme interfere with steroidal hydroxylation, thereby 
FIGURE 1 Duration of tamoxifen use versus age for the amen-
orrheic tamoxifen users tested with the forced-response color-
 naming paradigm detailed in Eisner & Incognito (2006).184 Open 
symbols represent subjects who called the threshold-level incre-
mental test stimulus “white”, and filled symbols represent sub-
jects who called this stimulus “lavender”. The test stimulus was 
a 3°  diameter short-wavelength (440 nm) disc that was square-
wave modulated at a rate of 1.5 Hz and was centered within an 
adapting background stimulus. The background was a moder-
ately bright (3.6 log troland) 11° diameter, yellow (580 nm) disc 
viewed for at least 5 minutes. The horizontal dashed line signifies 
2 years of tamoxifen use. (Data from three tamoxifen users who 
called the  stimulus “blue” are omitted. For one of these subjects, 
the sensitivity was grossly reduced;184 the other two subjects were 
ages 56.8 and 59.5 years, and used tamoxifen for 4.0 and 4.9 years, 
respectively.) This graph has not been published previously.
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inhibiting estrogen synthesis.232 Exemestane is a 
 steroidal AI that structurally resembles the androgen 
 androstenedione and interacts with the substrate bind-
ing site of the aromatase enzyme, ultimately leading 
to the enzyme’s irreversible inactivation (meaning 
that the subsequent production of estrogen requires 
 aromatase to be synthesized anew).232, 233 Each AI 
reduces aromatization by more than 97%, with letro-
zole being slightly more effective in this regard than 
anastrozole.230 The effects of exemestane at this high 
level of suppression are more difficult to compare, for 
technical reasons involving the steroidal properties of 
exemestane.230
Many, but not all, of the extensively documented 
side effects of AIs resemble those of tamoxifen,5, 31 
but relatively little is known about the effects of AIs 
on the visual system. The resemblance is expected to 
be imperfect because tamoxifen (despite often being 
referred to as an “anti-estrogen”) is a SERM, whereas 
the effects of AIs on human physiology are more strictly 
anti-estrogenic. This difference makes AIs more useful 
for modeling effects of female aging on vision and the 
eye. One must nevertheless exercise caution when inter-
preting the observed effects of an individual AI such 
as anastrozole as an AI class effect or as an estrogen-
deprivation effect. Corroborating evidence is needed, 
since second-order effects on testosterone levels may 
differ between AIs, for example.234,235
Two studies by Eisner et al. (2008)177 and (2009)181 
researched the ability of anastrozole to induce retinal 
changes detectable ophthalmologically. (A third study, 
Eisner et al. (2007),178 found that anastrozole did not 
affect the ONH, whereas tamoxifen did; this study was 
described in the preceding section.) These three studies 
all employed a cross-sectional methodology to evaluate 
data from early-stage BC survivors using anastrozole 
monotherapy. The test subjects all had excellent visual 
acuity, no history of eye disease or diabetes, and no high 
myopia; and they were younger than 70 years. Control 
subjects were age-matched amenorrheic women without 
BC histories and not using any hormonal medication. 
Amenorrheic BC survivors using tamoxifen mono-
therapy were also tested
For the first of the two retinal studies, four of 35 
(11.4%) of the anastrozole users were found to have a 
small retinal hemorrhage in the posterior pole of one eye, 
based on masked assessment of fundus photographs by 
an ophthalmologist.177 This 11.4% proportion was signif-
icantly greater than the corresponding proportions for 
control subjects and for tamoxifen users.177 Two of the 
four anastrozole users had a flame hemorrhage (in the 
nerve fiber layer), two had a blot hemorrhage (deeper 
in the retina), and all four apparently were asymptom-
atic. However, a small hemorrhage nearer to the fovea 
could be symptomatic. Indeed, a 47-year-old anastro-
zole patient who noticed a grey spot while reading was 
referred to an ophthalmologist who detected a small 
juxtafoveal hemorrhage (AE, unpublished case report). 
This relatively young patient, who was not a subject in 
our studies, was also taking a GnRH agonist.
Because small hemorrhages can resorb within 
months,236 the incidence rate of anastrozole-induced 
retinal hemorrhages over a 5-year period is expected 
to be higher than the corresponding prevalence rate 
based on a cross-sectional snapshot, which provided 
the basis for the 11.4% rate reported by Eisner et al. 
(2008)177 for their small but select sample. On the 
other hand, the hemorrhages observed by Eisner et al. 
(2008)177 might have not have resulted solely or directly 
from the AI itself. Instead, they might have arisen at 
least partly from the actions of additional drugs used 
to relieve muscle or joint pain (aspirin) or to preserve 
bone  density (bisphosphonates).177 This possibility is 
discussed in greater detail and in a more general con-
text in the next section. Because the retinal hemorrhages 
were subtle, comparable hemorrhages might be missed 
in a cursory eye exam, or in an eye exam by someone 
other than an eye care specialist. The hemorrhages 
observed by Eisner et al. (2008) did not result from high 
blood pressure,177 but excessive traction pulling on the 
retina may have been a factor,181 as menopause appears 
to increase the risk for several vitreo-retinal tractional 
conditions.237–241
To observe and quantify effects of traction on reti-
nal anatomy, Eisner et al. (2009)181 transformed retinal 
thickness data obtained using time-domain OCT into 
foveal shape profiles corresponding to a slice along 
the horizontal (i.e., nasal/temporal) meridian. The 
effects of traction between the vitreous and retina 
then could be measured and compared across subject 
groups. As  predicted, the foveal shapes of anastrozole 
users were distorted in a manner consistent with a 
 heightened degree of vitreo-retinal traction, with the 
upper  portion of the temporal side of the foveal slope 
displaced towards the ONH, an asymmetrically located 
major anchor for the vitreous.242 The results181 are shown 
graphically in Figure 2. The nasal-temporal asymmetries 
differed significantly between anastrozole users and 
control subjects, but the corresponding asymmetries for 
tamoxifen users appeared to be intermediate to those 
of the other two groups and the statistical comparisons 
were inconclusive.181
The data for Figure 2 were analyzed for subjects 
without discernible posterior vitreous detachments 
(PVDs), and in fact, the tamoxifen users without PVDs 
were observed to have used tamoxifen for a significantly 
shorter duration than the tamoxifen users with PVDs.181 
(Most subjects’ PVDs evidently were partial rather than 
complete.181) Among anastrozole users, it is likely that 
the heightened degree of  traction resulted from estrogen 
depletion, since PVDs237 and macular holes238, 239 each 
are traction-related  conditions that occur more often in 
women than in men, and moreover, may be precipitated 
by the menopausal transition.240,241 Estrogen supplemen-
tation might even protect against the  development of 
macular holes.238 Thus, AIs may increase the risk of 
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macular holes or other relatively acute  traction-related 
 conditions such as rhegmatogenous retinal detach-
ments.243 Any patient reporting  worsening floaters or 
photopsia should be promptly referred by their oncolo-
gist to an ophthalmologist. In our clinical experience 
(author SWL), about 1 in 30 AI users mention that these 
entoptic phenomena develop or worsen with AI use.
Eisner et al.181 noted in retrospect that their anastro-
zole subjects were, on average, less myopic than were 
their subjects in the tamoxifen and control groups. 
This observation suggested a possible recruitment bias 
wherein disproportionately many myopic anastrozole 
users did not enroll in the study, possibly because they 
felt their vision was no longer normal. Epstein244 sub-
sequently published a case report on the  deterioration 
of visual acuity in two myopic BC survivors who 
switched from a non-steroidal AI to exemestane; one 
developed a macular hole after the switch. Myopia is a 
known risk factor for PVDs237 and macular holes,245 and 
when combined with excessive vitreo-retinal traction, 
a shearing force can be created at the fovea.181 In 2004, 
the Intergroup Exemestane Study (IES) had reported 
that early-stage BC survivors who had switched from 
tamoxifen to exemestane after 2–3 years were signifi-
cantly more likely to develop visual disturbances than 
were women who remained on tamoxifen, but the 
types of disturbances were not specified.246 It would 
be desirable and feasible to test BC survivors before 
and after they switch from tamoxifen to an AI in order 
to determine whether the switch leads to measurable 
intraocular change, particularly as assessed with 
spectral-domain OCT.
The eye is unique among all the organs of the body 
in that its interior can be viewed and measured with 
an extraordinarily high degree of precision. Thus, 
changes in intraocular anatomy are potentially useful 
for  marking and tracking changes elsewhere in the body 
that result from AI use. Of all AI side effects, the one 
most often leading to medication non-compliance is 
arthralgia (joint pain).247 The strong degree of biochemi-
cal similarity between joints and vitreous242,248–250 raises 
the possibility that measured changes in vitreo-retinal 
traction might be useful in helping to mark changes in 
joints that accompany the development of AI-induced 
arthralgia,251, 252 and that are likely to result from a 
decrease in estrogen synthesis.253 This is a matter for 
future study.
The same types of color perception changes experi-
enced by tamoxifen users184 also were experienced by 
anastrozole users,182 but with an important difference. 
That is, whereas the effects of tamoxifen depended on the 
duration of use,184 the effects of anastrozole depended on 
age, with the anastrozole users who  perceived the test 
stimulus as white being significantly younger (by about 
6 years on average) than the  anastrozole users who 
perceived it as colored.182 Because  estrogen  production 
 normally is greater for younger  post-menopausal 
women than for older post-menopausal women,254, 255 
this result suggests that the anastrozole-induced change 
in estrogen exposure, rather than just the low estrogen 
levels themselves, led to the perception of white.182 
Bear in mind that because the perception of white was 
elicited for a very  specific set of laboratory conditions 
(a short-wavelength test stimulus flashed on a larger, 
moderately bright, yellow background), this perception 
need not reflect either a more  generalized or real-word 
color vision deficit wherein hues appear desaturated. 
Instead, the  perception of white more likely manifests 
a  reduction of processing speed within the functionally 
isolated neural substrate responsible for SWS-cone-
mediated vision.182 Future studies should directly test 
the hypothesis that AIs prolong the temporal integration 
(neural summation) periods for SWS-cone-mediated 
response, since if AIs cause SWS-cone-mediated 
response to become more sluggish, the likelihood is 
strong that the  temporal response  properties of some 
other CNS neural  substrates are altered similarly. 
Cognitive processing speed, for example, may be slowed 
by anastrozole use,256,257 and senses such as hearing that 
depend exquisitely on response timing might also be 
vulnerable to reductions of estrogenic activity.258,259
In unpublished results (author AE), the monocular 
contrast sensitivities of anastrozole users were found 
to be significantly lower (average difference = 0.08 
log units, corresponding to ~½ line of loss on the 
 Pelli-Robson chart) than those of female control  subjects 
FIGURE 2 Foveal shape profiles normalized to the locus of 
 minimal retinal thickness; nasal direction is to the left, and tempo-
ral to the right. Squares (☐) represent median data of anastrozole 
users, circles (◯) represent median data of control subjects, and 
crosses (×) represent median data of tamoxifen users. Connecting 
lines are unbroken for the anastrozole users and control subjects, 
and dashed lines are for the tamoxifen users. All units are microns 
(μm). Note that the scales on the two axes differ. The locus of 
minimal thickness defines a height of 0 μm on the ordinate. Data 
are derived from subjects without detectable PVDs. This figure 
was previously published as Figure 1 in (Eisner, Thielman, 
Falardeau, Vetto Vitreo-retinal traction and anastrozole use. Breast 
Cancer Res Treat. 2009;117:9–16),181 but with a different legend 
and title. The graph is reproduced with kind permission from 
Springer Science+Business Media B.V.
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and tamoxifen users, respectively. Thus, the spatial 
vision of anastrozole users was affected despite their 
excellent acuity. Contrast sensitivity should be assessed 
for AI users reporting unexplained vision difficulties.
One final note: Although chronic dry eye can 
 appreciably impact quality of life,260 and there are 
 physiological and epidemiological reasons for 
 supposing that AI usage can lead to dry eye, only 
one study appears to have expressly raised this 
 possibility.261 ERs are present in the cornea16 and tear 
film glands,16,18,22,23 conditions such as premature ovarian 
failure apparently can lead to dry eye,262 and dry eye 
is most prevalent among post-menopausal women.3,62 
While these considerations suggest that the abrupt 
reduction of estrogen synthesis can lead to dry eye, the 
relation of hormonal activity to dry eye evidently is 
more complex, as it is now seems likely that androgen/
estrogen balances are more important than estrogen 
exposure alone for  maintaining the ocular surface and 
for minimizing ocular surface discomfort.3,263,264 Either 
view justifies conducting studies to determine whether 
AIs may contribute to the development or exacerbation 
of dry eye. An objective and practical measure of tear 
film osmolarity has been reported recently to correlate 
well with dry-eye severity as assessed subjectively,265 so 
we propose that studies relating tear film osmolarity to 
BC treatment be conducted along with administration 
of a validated survey tool. Osmolarity measurements 
can be performed quickly and easily, and hence can be 
appended to clinical trials or other studies.
MEDICATIONS USED FOR REDRESSING 
SIDE EFFECTS OF BC TREATMENTS
Hot flashes are a relatively common side effect of 
tamoxifen and of all the AIs.5,31 Because  supplemental 
estrogen is contraindicated for most BC survivors, 
they are instead often prescribed serotonin specific 
reuptake inhibitors (SSRIs) for symptomatic relief.266 
SSRIs also are prescribed as anti-depressants.267 
However, at least several different SSRIs, notably 
paroxetine (Paxil®) and fluoxeteine (Prozac®) but 
not citalopram (Celexa®), strongly interfere with the 
ability of CYP2D6 to  convert tamoxifen to its active 
metabolites, particularly endoxifen.162,268 Consequently, 
women using tamoxifen are no longer routinely pre-
scribed SSRIs that are potent CYP2D6 inhibitors. SSRI 
usage remains common among tamoxifen and AI users, 
and several percent of SSRI users overall have been 
reported to complain of “blurry vision,” possibly due 
to a mydriatic effect.269,270 Interestingly, metabolism of 
the intraocular pressure drug timolol depends on the 
activity of the same CYP2D6 enzyme as tamoxifen, so 
patients with low CYP2D6 activity may be at increased 
risk for beta-blocker induced brachycardia following 
systemic absorption of ophthalmically-administered 
timolol.271–273 Oncologists should be aware that the 
glucocorticoid dexamethasone, one of several types of 
drugs used for anti-emesis while patients are receiving 
chemotherapy,274 can acutely raise intraocular pressure 
in susceptible people.275,276
Because AIs reduce bone density, women who 
are prescribed an AI are sometimes also prescribed a 
bisphosphonate,277 a type of medication that decreases 
bone resorption by disrupting osteoclast function.278 
However, bisphosphonates can have serious side 
effects,279 so they are not prescribed merely as a  matter 
of course.280 It has become clear that bisphospho-
nates, especially the ones administered intravenously, 
 occasionally lead to clinically significant uveitis and 
scleritis, generally of the anterior portion of the eye.281–283 
The intravenously administered bispshosphonate zolen-
dronate (Zometa®) may have anti-cancer properties in 
its own right,284 so several clinical trials are underway 
to determine whether and how zolendronate should 
be added to existing AI regimens.285 The preliminary 
results regarding upfront use of zolendronate (adminis-
tered at 6-month intervals) combined with daily AI use 
indicate that BC recurrence rates are reduced.286 Thus, 
the use of zolendronate is likely to increase in the future, 
in which case, the rates of uveitis and scleritis among 
BC survivors will also likely increase.
The small retinal hemorrhages detected in a sig-
nificant proportion of anastrozole users177 (see the 
 previous section) might also have depended in some 
cases on the use of supplemental medications for 
alleviating AI-induced side effects. Of the four out of 
35   anastrozole users with retinal hemorrhages, the two 
with blot  hemorrhages were the only anastrozole users 
also using both a bisphosphonate (taken orally) and 
aspirin.177 These limited data suggest that blot hemor-
rhages can result from a drug combination that includes 
an AI and a bisphophonate acting synergistically on the 
posterior portion of the eye. Bisphosphonates may affect 
the posterior uvea at a greater rate than is recognized,287 
and estrogen depletion might increase retinal vascular 
permeability.288
DIRECTIONS FOR FUTURE RESEARCH
Although treatments for BC are continually  evolving, it 
seems certain that millions of BC survivors will receive 
adjuvant endocrine therapy involving years of AI use. 
What remains unknown is the scheduling of this treat-
ment. Will AIs be prescribed after 2–3 years of tamoxifen 
use, or will AIs be used from the outset? Will patients 
receive adjuvant endocrine therapy for more than 
5 years? Which AIs will be used, and how might their 
visual and ocular effects differ? How might prior use of 
tamoxifen interact with the ability of an AI to affect vision 
and the eye? This last question is  important because 
many post-menopausal women may be using tamoxifen 
for the first several years at the start of a tamoxifen/
AI switching regimen, while many other women will 
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have taken tamoxifen for varying periods of time before 
reaching the menopause. Tamoxifen will continue to 
serve as an alternative medication for  post-menopausal 
women whose AI side effects are unacceptable, and it 
is expected to remain a mainstay for men with BC.
Because iatrogenic (treatment-induced) changes to 
vision or the eye may impact BC survivors’  quality 
of life and hence reduce adherence to treatment, such 
changes may indirectly cause BC recurrence rates 
to increase. Iatrogenic changes may also sometimes 
be misattributed to natural aging. Thus, studies are 
needed to determine whether AIs contribute to the 
development or exacerbation of dry eye, and if they 
do contribute, then which AIs contribute most and in 
which regimens. These dry-eye studies should include 
measures of tear-film osmolarity. We also suggest that 
studies be conducted to evaluate the ability of Als to 
produce traction capable of altering the existing relation 
between the vitreous and retina. These studies should 
include quantitative assessments of foveal shape indices 
derived from retinal thickness measurements made with 
spectral-domain OCT devices. Assessing vitreo-retinal 
traction is important because excessive traction (a) may 
produce entoptic symptoms that disturb or concern 
patients in the short-term, and (b) may raise the risk for 
subsequent sight-threatening conditions such as macu-
lar holes. Perhaps even more importantly, evidence is 
accumulating to suggest that increased traction may 
raise the long-term risk for blinding conditions such as 
macular degeneration.38,289–291 Thus, we recommend that 
oncologists routinely query AI users about the develop-
ment of traction-related symptoms such as floaters or 
photopsia. We also recommend that AI users be queried 
about changes in ocular surface discomfort and that 
contrast sensitivities be routinely assessed, which is 
feasible in an oncology setting. Worsening of any these 
factors may warrant referral to an ophthalmologist.
Because drugs that drastically reduce ER activity 
can be administered to people only with compelling 
 clinical justification, the widespread use of AIs provides 
a unique chance to investigate the means by which 
estrogen deprivation (or conversely, estrogen exposure) 
affects the adult human visual system, particularly for 
women at and beyond menopause. These investigations 
should include studies of the etiology of traction-related 
intraocular conditions such as PVDs and macular holes. 
Moreover, because the eye is so accessible and visual 
response is so quantifiable, measures of the eye and 
vision might also be assessed for their ability to mark 
related iatrogenic changes occurring in parts of the body 
that are more difficult to view and/or quantify. For 
example, the use of OCT to quantify AI-induced ana-
tomical changes at the vitreo-retinal interface might be 
investigated as a means for marking coincident changes 
occurring in joints247 (and which have long been postu-
lated to share a common etiology with eye changes292,293). 
Because commercial OCT devices are widely distributed 
and are not intimidating to patients, OCT is well-suited 
for use in longitudinal studies, whether conservative or 
more speculative.
Similarly, future investigations should include assess-
ments of visual functions susceptible to changes in 
estrogenic activity. Because SWS-cone-mediated visual 
response is important only for color vision and not, 
for instance, for fine spatial resolution,294 AI-induced 
changes in SWS-cone-mediated response182 are not 
expected to compromise a person’s ability to function 
in her environment. By the same token, however, SWS-
cone-mediated response sensitivities can be measured 
using established procedures that provide an exception-
ally high degree of functional isolation,216,295,296 thereby 
allowing the response dynamics of an operationally 
well-defined neural substrate to be measured behav-
iorally with little or no intrusion from other neural 
substrates182 (which do not share the same pre-cortical 
anatomic pathways dedicated to SWS-cone-mediated 
vision297,298). If the temporal integration periods of SWS-
cone-mediated response are prolonged by AI use, as we 
hypothesize, there is only a remote chance that no other 
neural substrate is made more sluggish in this way. We 
therefore suggest that psychophysical studies be con-
ducted to determine whether AIs cause the temporal 
integration periods for SWS-cone-mediated response to 
become prolonged. (Corresponding fMRI studies may 
be performed,299,300 but because of practical  constraints, 
fMRI studies are limited to small numbers of subjects.) 
If our hypothesis is supported, a next step is to deter-
mine whether response sluggishness measured for 
SWS-cone-mediated vision can be used to mark  deficits 
in cognitive processing that may result from one or 
more adjuvant endocrine therapies.224 For the present, 
we recommend that studies of BC survivors’ cognitive 
function begin to record or screen for eye health and 
also add tests of spatial vision so that sensory deficits 
are not misconstrued as cognitive deficits.206
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NOTICE OF CORRECTION
The Early Online version of this article published online ahead of print on 5 August 2011 contained errors.
 The start of the Abstract on page 867 has been changed from "This review concerns the visual and ocular 1. 
effects..." to "This review concerns the effects on vision and the eye..."
The original receipt date has been added at the bottom of page 867.2. 
Capitalization has been corrected in the section heading on page 873.3. 
These errors have been corrected for the current version.
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